ABSTRACT Combined low-dose radon/hyperthermia therapy has been reported to improve pain and mobility in patients with rheumatic disorders. The key feature of inflammatory rheumatic diseases is the induction of autoimmune processes via the production of autoantibodies. As reducing the autoantibody level through administration of biologicals is described to correlate with delay of disease progression, we investigated the impact of combined low-dose radon/hyperthermia therapy on the serum levels of antibodies directed against cyclic citrullinated peptides in patients with ankylosing spondylitis. We found that levels of circulating anti-CCP antibodies is significantly reduced immediately after a 3 weeks of radon therapy regimen.
Cite this paper
nullModer, A. , Hufnagl, C. , Jakab, M. , Hitzl, W. and Ritter, M. (2011) Radon-therapy in ankylosing spondylitis reduces auto-antibody titers. Open Journal of Molecular and Integrative Physiology, 1, 52-54. doi: 10.4236/ojmip.2011.13008.
 Van Der Helm-Van Mil, A.H., Wesoly, J.Z. and Huizinga, T.W. (2005) Understanding the genetic contribution to rheumatoid arthritis. Current Opinion in Rheumatology, 17, 299-304. doi:10.1097/01.bor.0000160780.13012.be
 Chapuy-Regaud, S., et al. (2005) IgG subclass distribu- tion of the rheumatoid arthritis-specific autoantibodies to citrullinated fibrin. Clinical and Experimental Immunol- ogy, 139, 542-550.
 Schellekens, G.A., et al. (1998) Citrulline is an essential constituent of antigenic determinants recognized by rh- eumatoid arthritis-specific autoantibodies. Journal of Cl- inical Investigation, 101, 273-281. doi:10.1172/JCI1316
 Schellekens, G.A., et al.(2000) The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis and Rheumatism, 43, 155-163.
 Nielen, M.M., et al. (2005) Antibodies to citrullinated human fibrinogen (ACF) have diagnostic and prognostic value in early arthritis. Annals of the Rheumatic Diseases, 64, 1199-1204. doi:10.1136/ard.2004.029389
 Rantapaa-Dahlqvist, S., et al. (2003) Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis and Rheumatism, 48, 2741-2749.
 Cambridge, G., et al. (2003) Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis and Rheumatism, 48, 2146-2154.
 Alessandri, C., et al. (2004) Decrease of anti-cyclic citr- ullinated peptide antibodies and rheumatoid factor fol- lowing anti-TNFalpha therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement. Annals of the Rheumatic Diseases, 63, 1218-1221.
 Atzeni, F., et al. (2006) Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citru- llinated peptide antibody titer reduction: A one-year prospective study. Arthritis Research and Therapy, 8, R3.
 Chen, H.A., et al. (2006) The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheuma- toid factor in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases, 65, 35-39.
 Vis, M., et al. (2008) IgM-Rheumatoid factor, anti-cyclic citrullinated peptide, and anti-citrullinated human fibri- nogen antibodies decrease during treatment with the tum- or necrosis factor blocker infliximab in patients with rh- eumatoid arthritis. Journal of Rheumatology, 35, 425-428.
 Van Tubergen, A., et al. (2001) Combined spa-exercise therapy is effective in patients with ankylosing spondyli- tis: A randomized controlled trial. Arthritis and Rhe- umatism, 45, 430-438.
 Berglin, E., et al. (2006) Radiological outcome in rheumatoid arthritis is predicted by presence of antibodies against cyclic citrullinated peptide before and at disease onset, and by IgA-RF at disease onset. Annals of the Rh- eumatic Diseases, 65, 453-458.
 Agrawal, S., Misra, R. and Aggarwal, A. (2007) Autoantibodies in rheumatoid arthritis: Association with severity of disease in established RA. Clinical Rheumatology, 26, 201-204.